Previous 10 | Next 10 |
2024-06-24 01:43:14 ET Summary Astria Therapeutics stock has fallen 40% since early 2023, but promising early data for its candidate STAR-0215 in treating HAE is helping drive analyst Buy ratings. ATXS stock has a compound called STAR-0310 in development for an immune disorder, wi...
2024-06-21 06:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors looking for long-term returns should consider investing in strong buy Cathie Wood stocks this month. The ARK Invest Chief Executive Officer ( CEO ) gained a massive following ...
2024-06-20 16:14:49 ET Summary We take our first look at gene editing concern Prime Medicine, Inc., whose stock was recently upgraded by Citigroup. The company has an extensive set of potential candidates in pre-clinical research and just advanced its first gene therapy asset in c...
CAMBRIDGE, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an abstract featuring redosing data from the Phase 1 stud...
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors. “We a...
2024-06-09 06:20:00 ET Cathie Wood is known for two things: picking out innovators that will go on to score a win over the long run, and getting in on these stocks at a great price. The founder and chief executive officer of Ark Invest doesn't mind going against the crowd and choosing compa...
2024-06-08 07:25:00 ET On June 2, Intellia Therapeutics ' (NASDAQ: NTLA) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words that are sure to make at least a few savvy investors sa...
2024-06-05 07:11:15 ET Summary Intellia Therapeutics has released positive data from its Phase I/II study of NTLA-2002, a CRISPR-based gene editing therapy. The study shows promising results for in vivo gene editing, offering potential treatments for genetic diseases. Robust t...
2024-06-04 17:30:03 ET Citigroup analyst issues UNDERPERFORM recommendation for NTLA on June 4, 2024 04:00PM ET. The previous analyst recommendation was Underperform. NTLA was trading at $23.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-06-04 17:30:03 ET Wedbush analyst issues NEUTRAL recommendation for NTLA on June 4, 2024 04:00PM ET. The previous analyst recommendation was Neutral. NTLA was trading at $23.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
News, Short Squeeze, Breakout and More Instantly...
Intellia Therapeutics Inc. Company Name:
NTLA Stock Symbol:
NASDAQ Market:
Intellia Therapeutics Inc. Website:
2024-07-13 10:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...